NSCLC (Issue 9) | Special Reports

November 16, 2015

Roman Perez-Soler, MD, talks about NSCLC tumors becoming resistance to chemotherapy and first-line treatment.

November 16, 2015

A study published in the Journal of Clinical Oncology found that an EGFR inhibitor, erlotinib, was well tolerated in combination with whole-brain radiation therapy for patients with brain metastases from NSCLC.

November 16, 2015

Immunotherapy is fast becoming the new standard of care for non-small-cell lung cancer alongside developing research in the field.

November 16, 2015

Dr Rolf A. Stahel, MD, and Dr Thomas E. Stinchcombe, MD, weigh in on treating patients with NSCLC.

November 16, 2015

A paper presenting the results of a retrospective study of patients with ALK-rearranged NSCLC hypothesized that prognosis for patients with NSCLC and brain metastases could be further identified through molecular subtyping.

November 14, 2015

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, talks about how immunotherapies targeting PD-L1 and PD-1 are showing activity in lung cancer.

November 14, 2015

Researchers are now searching for chemical or genetic biomarkers that could be used to identify lung cancer patients more likely to develop brain metastases.

November 14, 2015

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.